Skip to main content
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems
  • Log in
  • My alerts
  • My Cart

Main menu

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • COVID-19 Special Collection
    • Archive
    • Minireviews
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About AAC
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • AAC Podcast
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems

User menu

  • Log in
  • My alerts
  • My Cart

Search

  • Advanced search
Antimicrobial Agents and Chemotherapy
publisher-logosite-logo

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • COVID-19 Special Collection
    • Archive
    • Minireviews
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About AAC
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • AAC Podcast
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions
Epidemiology and Surveillance

Clinical and Molecular Correlates of Escherichia coli Bloodstream Infection from Two Geographically Diverse Centers in Rochester, Minnesota, and Singapore

Shehara M. Mendis, Shawn Vasoo, Brian D. Johnston, Stephen B. Porter, Scott A. Cunningham, Sanjay R. Menon, Christine B. Teng, Partha P. De, Robin Patel, James R. Johnson, Ritu Banerjee
Shehara M. Mendis
aDepartment of Laboratory Medicine, Tan Tock Seng Hospital, Singapore
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Shawn Vasoo
bNational Centre for Infectious Diseases, Singapore
cDepartment of Infectious Diseases, Tan Tock Seng Hospital, Singapore
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Shawn Vasoo
Brian D. Johnston
dMinneapolis Veterans Affairs Health Care System, Minneapolis, Minnesota, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Stephen B. Porter
eUniversity of Minnesota, Minneapolis, Minnesota, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Scott A. Cunningham
fDivision of Clinical Microbiology, Mayo Clinic, Rochester, Minnesota, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sanjay R. Menon
aDepartment of Laboratory Medicine, Tan Tock Seng Hospital, Singapore
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Christine B. Teng
gDepartment of Pharmacy, National University of Singapore, Singapore
hDepartment of Pharmacy, Tan Tock Seng Hospital, Singapore
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Partha P. De
aDepartment of Laboratory Medicine, Tan Tock Seng Hospital, Singapore
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Robin Patel
fDivision of Clinical Microbiology, Mayo Clinic, Rochester, Minnesota, USA
iDivision of Infectious Diseases, Mayo Clinic, Rochester, Minnesota, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Robin Patel
James R. Johnson
dMinneapolis Veterans Affairs Health Care System, Minneapolis, Minnesota, USA
jDepartment of Medicine, Division of Infectious Diseases and International Medicine, University of Minnesota, Minneapolis, Minnesota, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ritu Banerjee
kDivision of Infectious Diseases, Department of Pediatrics, Vanderbilt University School of Medicine, Nashville, Tennessee, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI: 10.1128/AAC.00937-18
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

ABSTRACT

Escherichia coli bacteremia is caused mainly by sequence type complex 131 (STc131) and two clades within its fluoroquinolone-resistance-associated H30 subclone, H30R1 and H30Rx. We examined clinical and molecular correlates of E. coli bacteremia in two geographically distinct centers. We retrospectively studied 251 unique E. coli bloodstream isolates from 246 patients (48 from the Mayo Clinic, Rochester, MN [MN], and 198 from Tan Tock Seng Hospital, Singapore [SG]), from October 2013 through March 2014. Isolates underwent PCR for phylogroup, STc, blaCTX-M type, and virulence gene profiles, and medical records were reviewed. Although STc131 accounted for 25 to 27% of all E. coli bacteremia isolates at each site, its extended-spectrum-β-lactamase (ESBL)-associated H30Rx clade was more prominent in SG than in MN (15% versus 4%; P = 0.04). In SG only, patients with STc131 (versus other E. coli STc isolates) were more likely to receive inactive initial antibiotics (odds ratio, 2.8; P = 0.005); this was true specifically for patients with H30Rx (odds ratio, 7.0; P = 0.005). H30Rx comprised 16% of community-onset bacteremia episodes in SG but none in MN. In SG, virulence scores were higher for H30Rx than for H30R1, non-H30 STc131, and non-STc131 isolates (P < 0.02 for all comparisons). At neither site did mortality differ by clonal status. The ESBL-associated H30Rx clade was more prevalent and more often of community onset in SG, where it predicted inactive empirical treatment. The clonal distribution varies geographically and has potentially important clinical implications. Rapid susceptibility testing and clonal diagnostics for H30/H30Rx might facilitate earlier prescribing of active therapy.

INTRODUCTION

The past 15 years have seen an unprecedented and rapid global expansion of a single Escherichia coli lineage, sequence type complex 131 (STc131), and specifically its fluoroquinolone-resistance-associated H30R subclone. H30R comprises sister clades H30R1 (or C1) and H30Rx (or C2), which are associated with the CTX-M-15 extended-spectrum β-lactamase (ESBL) (1, 2). The emergence of STc131 is the main basis for the rise in fluoroquinolone and ESBL resistance in E. coli. STc131 isolates typically harbor multiple virulence factors (1, 3) and are associated with diverse extraintestinal infections, including bacteremia (1, 2).

Although infections due to ESBL-producing Enterobacteriaceae, including STc131, have traditionally been associated with health care exposure (i.e., health care associated) (4), the boundaries between health care- and community-associated infections with respect to the associated clones are becoming increasingly blurred. In areas of low ESBL prevalence, community-onset infections due to ESBL-producing E. coli (including STc131) may be related to antibiotic use and travel to regions of higher ESBL endemicity, in addition to health care exposure (5, 6). Indeed, community transmission of STc131 is well documented (7), including between family members (8), and appears to be more common between household than nosocomial contacts (9). In areas of high ESBL endemicity, such as countries in Asia, STc131 is well established in the community and accounts for up to one-third of community-onset ESBL E. coli bacteremias (10, 11). The emergence of extensively resistant lineages of STc131 E. coli, such as H30Rx, as a cause of community-onset infections is reminiscent of the emergence of another concerning multidrug-resistant (MDR) pathogen, community-associated methicillin-resistant Staphylococcus aureus.

Few data are available regarding the molecular epidemiology of antimicrobial-resistant E. coli infections in Singapore (SG). ESBL-producing Enterobacteriaceae emerged in Singapore in the mid-1980s, associated initially with TEM/SHV-type enzymes, which by the late 1990s were supplanted by CTX-M-type enzymes. Among 46 recent cefotaxime-nonsusceptible E. coli bloodstream isolates from Singapore, STc131 accounted for more of the community-onset isolates (23/34; 68%) than the health care-associated isolates (6/12; 50%) (12). Additionally, few studies from any locale have attempted to correlate the E. coli clonal distribution with detailed, patient-level clinical data.

Here we sought to define the molecular epidemiology (clonal background, resistance, and virulence genotype) of contemporaneous E. coli bloodstream isolates from two distinct geographical locations with different antimicrobial resistance rates: Rochester, MN (here MN), which has a low prevalence of ESBL-producing Enterobacteriaceae, including E. coli (13, 14), and Singapore, which has comparatively high rates (15). Specifically, we sought to determine if the locale-specific differences in resistance prevalence reflect differences in clonal distribution and whether clonal background corresponds with health care- or community-associated origin or clinical outcomes.

(These data were presented, in part, at the 27th European Congress of Clinical Microbiology and Infectious Diseases, Vienna, Austria, 22 to 25 April 2017, and the Singapore Health and Biomedical Congress, 12 to 14 October 2017.)

RESULTS

Study isolates.Forty-eight unique E. coli isolates were obtained from the 48 MN patients, while 203 unique E. coli isolates were obtained from the 198 SG patients, 194 of whom had a single morphotype and 4 of whom had multiple morphotypes (3 with 2 morphotypes each and 1 with 3 morphotypes). Hence, 251 isolates underwent molecular characterization for phylogenetic group, STc, virulence factors, and blaCTX-M (Table 1; see also Table S1 in the supplemental material).

View this table:
  • View inline
  • View popup
TABLE 1

Molecular characteristics of 251 Escherichia coli blood isolates

Phylogenetic groups, sequence types, subclones, blaCTX-M status, and extended-virulence genotypes.A significantly higher proportion of E. coli bacteremia isolates qualified molecularly as extraintestinal pathogenic E. coli (ExPEC) in SG (75%; 153/203) than in MN (54%; 26/48) (P = 0.003), with almost all of the H30Rx isolates being ExPEC at both sites, but 92% versus 56% of H30R1 isolates qualified as ExPEC in SG and MN, respectively (see the supplemental material). Phylogenetic and clonal groups were distributed similarly at the two sites (Table 1), with phylogroup B2 accounting for 60 to 62% and STc131 accounting for 25 to 27% of isolates. In both SG and MN, phylogroup B2, and especially STc131, was overrepresented compared to other phylogroups or clonal groups (P < 0.001 for all comparisons [one-sample chi-square test]). Likewise, among the STc131 isolates from SG, compared to other subclones and clades, the H30 subclone was overrepresented, as was H30Rx within the H30 subclone (P values of <0.001 and 0.004, respectively [one-sample chi-square test]). Although STc131 accounted for about one-quarter of the E. coli bacteremia episodes at both sites, H30Rx was significantly more prevalent overall in SG than in MN (15% versus 4%; P = 0.04). blaCTX-M-15 was associated closely with H30Rx (P < 0.001) among the SG but not the MN isolates.

Overall, SG isolates had higher virulence scores than the MN isolates (medians of 12 versus 10.5; P = 0.03 by a Mann-Whitney U test). Virulence gene profiles and scores varied significantly in relation to H30 subclone status (see the supplemental material). At both sites, H30Rx isolates had significantly higher virulence scores than the H30R1 isolates (medians of 14 [range, 13 to 15] versus 11 [range, 9 to 12] [P = 0.036] for MN and 14 [range, 10 to 16] versus 13 [range, 11 to 14] [P < 0.001 by a Mann-Whitney U test] for SG).

Clinical characteristics, bacterial variables, and outcomes at both sites.Analysis of associations between MN and SG clinical data included only patients with a single E. coli morphotype (n = 242; 48 from MN and 194 from SG) (Tables 2 to 4). Genders, ages, Charlson comorbidity indexes, and Pitt bacteremia scores were similar at both sites (Table 2). A higher proportion of MN patients received immunosuppressive medications (P = 0.006), were neutropenic (P = 0.004), had undergone solid-organ or stem cell transplantation (P < 0.001), or were admitted to the intensive care unit (P < 0.001). At both sites, the most common source of bacteremia was the urinary tract, followed by an intra-abdominal infection (Table 2). Non-E. coli organisms were recovered from blood along with E. coli more commonly in SG than in MN (9.3% versus 0%; P = 0.028). At both sites, community-onset episodes predominated (88% for SG and 85% for MN) over hospital-onset episodes (12% for SG and 15% for MN).

View this table:
  • View inline
  • View popup
TABLE 2

Clinical characteristics of 242 patients with Escherichia coli bacteremia in Singapore and Rochester, MN

View this table:
  • View inline
  • View popup
TABLE 3

Characteristics of Escherichia coli bloodstream infections by locale and STc131 and H30Rx status

View this table:
  • View inline
  • View popup
TABLE 4

Univariable and multivariable predictors of 30-day all-cause mortalitya

In SG, H30Rx appeared to have undergone community expansion in that it accounted for 27 (16%) of 170 community-onset bacteremia episodes (Fig. 1). Of these 27 community-onset episodes, 11 were fully community associated, while 16 were health care associated. In contrast, in MN, H30Rx caused none of the 41 community-onset bacteremia episodes (16 community and 25 health care associated) (Fig. 1).

FIG 1
  • Open in new tab
  • Download powerpoint
FIG 1

Distribution of Escherichia coli bloodstream infection episodes in Minnesota (MN) and Singapore (SG) by location of onset. (A) Hospital-onset infections; (B) community-onset infections. Statistically significant differences and associated P values are indicated with *.

Regarding outcomes, the SG and MN cohorts did not differ significantly for either the proportion of patients who received active antimicrobials 0, 24, or 48 h after the availability of the Gram stain result (data not shown) or 30-day mortality (Table 2). However, in SG, patients with an STc131 or an H30Rx isolate were less likely to receive an active antimicrobial agent at the time when the Gram stain was reported (Table 3).

Epidemiological, clinical, and bacterial variables were examined as predictors of mortality using both univariable and multivariable logistic regression analyses (Table 4). In the final models, mortality was predicted significantly only by the Pitt bacteremia score in SG and only by the age-adjusted Charlson comorbidity score in MN.

DISCUSSION

We assessed the clinical and associated bacterial characteristics of contemporaneous patients with E. coli bacteremia in two locales that differ greatly for the background prevalence of antimicrobial resistance. Our findings support four main conclusions. First, since its emergence in approximately 2000 (1), STc131 and its H30 subclone have disseminated and expanded impressively, now comprising approximately 25% of bloodstream isolates at each of our geographically separated study sites. Second, despite the relatively similar proportions of E. coli bacteremia episodes caused by STc131 at each site, the ESBL-associated H30Rx clade was significantly more prevalent in SG than in MN and concerningly accounted for 16% of community-onset infections, whereas in MN, no community-onset H30Rx bacteremia was detected. Third, while the H30Rx subclone had a larger number of virulence factors and a correspondingly higher virulence score, mortality did not correlate with the clonal background, specific virulence factors, or the virulence score, suggesting that other factors (e.g., host characteristics) may play a more important role in outcomes. Fourth, H30Rx bacteremia was associated with delayed receipt of active antimicrobial therapy in SG.

The finding that at both sites, phylogroup B2 accounted for ∼60% and STc131 accounted for ∼25% of isolates agrees with older and more contemporary estimates (16–19), including a recent U.S.-wide 2011–2012 survey (20). This concordant observation reaffirms that STc131 has disseminated successfully as a global clone, possibly facilitated by some combination of enhanced virulence (for which empirical support is largely lacking), high metabolic potential, and increased transmissibility and colonization ability (1, 21). These characteristics, along with a propensity to accumulate antimicrobial resistance genes without incurring a significant fitness cost, pose a challenge to clinicians managing infections caused by E. coli, a leading Gram-negative pathogen in both community and hospital settings.

H30Rx was significantly more prominent in SG than in MN (15% versus 4% overall; 70% versus 15% of ST131-H30 isolates), although the prevalences of STc131 and H30 clones were similar at both study sites. This suggests that within different geographic locales, certain unique factors may drive the differential expansion of distinct H30 clades. We hypothesize that the larger H30Rx fraction that we observed in SG may be due to comparatively greater antimicrobial pressure in SG, leading to preferential clonal expansion of the more-extensively resistant H30Rx lineage. Numerous studies document associations of prior antibiotic exposure with the subsequent isolation of multidrug-resistant E. coli (22–24). In the SG cohort, the proportions of patients with prior antibiotic use were 36% for the preceding year and 11% for the preceding month. Comparable data were not available for the MN cohort and although estimates of standardized antimicrobial use suggest higher rates for the United States overall than for SG (25), MN has comparatively lower antibiotic utilization rates than other U.S. states (26, 27) and, thus, may have a lower rate of utilization than SG.

Another possible contributor to the higher prevalence of H30Rx in SG is that SG is an international hub, visited frequently by travelers from within and beyond Asia, that relies heavily on imported food sources. Thus, ESBL-producing Gram-negative organisms (including ST131-H30Rx) from more highly endemic locales may be introduced through these routes (28).

The high prevalence of H30Rx that we observed among community-onset E. coli bacteremia isolates in SG (16% overall; 10% of community-associated and 25% of health care-associated isolates) (Fig. 1) poses a therapeutic challenge for providers, especially for patients without health care-associated risk factors. Such patients may be at risk of receiving ineffective initial antimicrobial therapy. In SG, at the time when Gram-negative bacilli were reported in blood cultures, patients with STc131 were 2.8-fold more likely than those with non-STc131 E. coli to be receiving inactive antibiotic therapy. The main driver of this phenomenon was H30Rx, with its 7-fold-higher likelihood of inactive therapy. Assuming that blood cultures typically flag positive within 24 to 72 h of incubation, our data suggest that in SG, patients with bacteremia due to STc131, and specifically H30Rx, were less likely than those with bacteremia due to other strains of E. coli to receive active antimicrobial therapy for up to ∼48 to 96 h after blood cultures were drawn. Whereas empirical antibiotic therapy was ineffective in 23% of SG patients overall, this rose to 55% for those with H30Rx, which suggests that clinicians are unaware of risk factors for H30Rx. In our study, while we did not detect a difference in 30-day mortality, other studies have found poorer clinical outcomes (e.g., prolonged hospitalization and clinical or microbiological persistence) with H30 infection and inactive antibiotic therapy (22, 29, 30). Further efforts should be directed toward identifying physician knowledge gaps in local antimicrobial resistance patterns and improving empirical prescribing practices via educational and stewardship efforts.

Rapid diagnostics to identify resistant subclones may facilitate the more timely institution of effective therapy. Previous studies have shown that PCR-based rapid clonal typing for E. coli directly on urine from patients with urinary tract infections may be rapid enough to inform the prescription of empirical antibiotics (31, 32). By using a clonotype-specific antibiogram on urine specimens, antibiotic/pathogen mismatch was reduced by more than 60% (31). Besides decreasing the use of ineffective antibiotics, such a strategy may allow the use of narrower-spectrum agents. Extrapolating from this, rapid clonal typing may also be useful for patients with bacteremia (e.g., positive blood cultures), possibly as part of a multiplexed molecular pathogen detection panel with other resistance markers, although further studies are needed.

Neither clonal background nor virulence genotype was associated with 30-day mortality. In contrast, multivariable analysis identified host factors, including the Pitt bacteremia score and Charlson comorbidity index, as correlates of mortality, which is in keeping with previous studies that found that host factors are more important than bacterial factors in determining the severity of E. coli bacteremia (19). Notably, other recent studies found that ST131-H30 was associated with older patients, compromised hosts, antimicrobial resistance, and clinical/microbiological persistence but not with key adverse outcomes (e.g., recurrence or mortality) (22, 33).

Limitations of this study include its retrospective nature, its inclusion of only a subset of E. coli bacteremia isolates from the two study sites, and the comparatively small number of isolates from MN, which limited statistical power. Study strengths include the relatively large overall study population and SG cohort, the comparisons of standardized clinical data with extensive molecular typing results, and the attention to key clonal subsets within STc131.

In summary, STc131 accounted for approximately 25% of bloodstream isolates at major medical centers in both MN and SG in 2013 to 2014. However, unlike in MN, where the most extensively resistant subclone, H30Rx, was not embedded in the community, in SG, H30Rx was prevalent and accounted for 16% of community-onset bacteremia and may thus be difficult to contain. Given that in SG, STc131, H30, and H30Rx were also associated with delayed institution of effective antimicrobial therapy, rapid susceptibility and clonal diagnostics for H30 and H30Rx may facilitate the earlier administration of active therapy. The clinical impact of rapid diagnostics for the detection of these subclones is likely to be greatest in locales like SG with a high endemic prevalence of resistant strains. The global dissemination of successful and antimicrobial-resistant clones such as STc131-H30 and H30Rx mandates continued vigilance and attention to local clonal epidemiology.

MATERIALS AND METHODS

Patients and E. coli bloodstream isolates.We retrospectively studied a convenience sample of 246 patients with E. coli bacteremia from October 2013 through March 2014 at the Mayo Clinic, Rochester, MN (here MN) (n = 48) and the Tan Tock Seng Hospital (TTSH), Singapore (here SG) (n = 198). The MN isolates were collected as part of a previous study and represented all available isolates from the second half of that study, when isolate collection was done (34). The SG isolates were a subset selected randomly with a computer-generated list from the hospital's larger collection of all E. coli bloodstream isolates during that period.

Both sites used BD Bactec Plus Aerobic/F and Anaerobic/F blood culture vials (Becton Dickinson, Sparks, MD), incubated on the Bactec 9240 system (SG) or the Bactec FX system (MN), and identified E. coli based on typical colonial morphology on selective agar plates (MacConkey agar [SG] or eosin methylene blue [MN]), supplemented by biochemical testing and matrix-assisted laser desorption ionization–time of flight mass spectrometry (MALDI-TOF MS) with the Bruker MALDI Biotyper (Bruker Daltonics).

Susceptibility testing was performed at SG by disk diffusion directly from positive blood cultures, using an in-house, laboratory-validated method similar to that described by Andrews et al. (35), and at MN by agar dilution using pure subcultures (36). Both sites used CLSI interpretive criteria (37). Screening for ESBL production was done in SG using the double-disk approximation method (38) and in MN based on cefpodoxime MICs, with values of >4 μg/ml being considered positive (37).

Molecular characterization and virulence scores.Phylogroups (phylogroups A, B1, B2, C, D, E, and F) were determined with the updated PCR-based Clermont method (39). Clonal groups that were resolved by PCR included STc131 and its sister clades H30Rx and H30R1, STc12, STc14/81/550, STc31 (O15:K52:H1), STc69 (“clonal group A” [CGA]), STc73, STc95, STc127, STc141, STc144, STc405, STc420, and STc648 (16, 40–42). Isolates were tested for blaCTX-M (universal), blaCTX-M-15, and the blaCTX-M-9 group (3, 43) and underwent extended virulence genotyping for 42 suspected or proven extraintestinal virulence-associated genes (44).

Clinical and epidemiological data.Medical records were reviewed for patient demographics, effectiveness of antimicrobial therapy, and mortality. Active antimicrobial therapy was defined as the presence in the electronic medical record of an order for an antibiotic to which the E. coli isolate was susceptible. This was assessed at the point when the blood culture Gram stain result was reported (0 h) and 24 and 48 h later.

Based on criteria modified from those described previously by Friedman et al., bacteremia episodes were classified as health care associated if the patient had been hospitalized ≥2 days in the preceding 90 days, was a resident in a nursing home or extended-care facility, received chronic dialysis within the preceding 30 days, or received any antibiotic within the 90 days prior to the E. coli bacteremia episode (45); all other episodes were classified as community associated. Community-onset bacteremia was defined as a bloodstream infection diagnosed from a blood culture drawn up to 48 h after admission; all other bacteremia episodes (positive blood cultures drawn beyond 48 h postadmission) were considered hospital-onset episodes. The severity of the bacteremia was calculated by using the Pitt bacteremia score (46).

Statistical methods.Categorical variables were compared with Fisher's exact test or a chi-square test, as appropriate. A one-sample chi-square test was used to examine differences between observed and expected (assuming an equal distribution of clonal groups) frequencies of E. coli clonal distributions at each site. Continuous variables were compared with the Mann-Whitney U test. To identify risk factors associated with all-cause 30-day mortality at each site, backward stepwise multivariable logistic regression was performed considering multiple models, including initially all variables with a univariable P value of <0.20. The final multivariable models included, as candidate predictors, all factors with a univariable P value of <0.05, plus H30Rx status (despite its lack of univariable significance). The Hosmer-Lemeshow statistic was used to assess goodness of fit. Analyses were performed by using SPSS version 21. P values of <0.05 were considered statistically significant. This study was approved by the institutional review boards of the Mayo Clinic and the National Healthcare Group, Singapore.

ACKNOWLEDGMENTS

This work was supported in part by Office of Research and Development, Department of Veterans Affairs, grants 1I01CX000920-01 and 2I01CX000920-04 (to J.R.J.) and National Institutes of Health grant 2KL2RR024151-07 (to R.B.).

We thank Vincent Chua for extracting data on recent antimicrobial use for the SG patients.

FOOTNOTES

    • Received 6 May 2018.
    • Returned for modification 6 June 2018.
    • Accepted 26 July 2018.
    • Accepted manuscript posted online 6 August 2018.
  • Supplemental material for this article may be found at https://doi.org/10.1128/AAC.00937-18.

REFERENCES

  1. 1.↵
    1. Banerjee R,
    2. Johnson JR
    . 2014. A new clone sweeps clean: the enigmatic emergence of Escherichia coli sequence type 131. Antimicrob Agents Chemother 58:4997–5004. doi:10.1128/AAC.02824-14.
    OpenUrlAbstract/FREE Full Text
  2. 2.↵
    1. Petty NK,
    2. Ben Zakour NL,
    3. Stanton-Cook M,
    4. Skippington E,
    5. Totsika M,
    6. Forde BM,
    7. Phan M-D,
    8. Gomes Moriel D,
    9. Peters KM,
    10. Davies M,
    11. Rogers BA,
    12. Dougan G,
    13. Rodriguez-Bano J,
    14. Pascual A,
    15. Pitout JDD,
    16. Upton M,
    17. Paterson DL,
    18. Walsh TR,
    19. Schembri MA,
    20. Beatson SA
    . 2014. Global dissemination of a multidrug resistant Escherichia coli clone. Proc Natl Acad Sci U S A 111:5694–5699. doi:10.1073/pnas.1322678111.
    OpenUrlAbstract/FREE Full Text
  3. 3.↵
    1. Banerjee R,
    2. Robicsek A,
    3. Kuskowski MA,
    4. Porter S,
    5. Johnston BD,
    6. Sokurenko E,
    7. Tchesnokova V,
    8. Price LB,
    9. Johnson JR
    . 2013. Molecular epidemiology of Escherichia coli sequence type 131 and its H30 and H30-Rx subclones among extended-spectrum-β-lactamase-positive and -negative E. coli clinical isolates from the Chicago region, 2007 to 2010. Antimicrob Agents Chemother 57:6385–6388. doi:10.1128/AAC.01604-13.
    OpenUrlAbstract/FREE Full Text
  4. 4.↵
    1. Banerjee R,
    2. Johnston B,
    3. Lohse C,
    4. Chattopadhyay S,
    5. Tchesnokova V,
    6. Sokurenko EV,
    7. Johnson JR
    . 2013. The clonal distribution and diversity of extraintestinal Escherichia coli isolates vary according to patient characteristics. Antimicrob Agents Chemother 57:5912–5917. doi:10.1128/AAC.01065-13.
    OpenUrlAbstract/FREE Full Text
  5. 5.↵
    1. Banerjee R,
    2. Strahilevitz J,
    3. Johnson JR,
    4. Nagwekar PP,
    5. Schora DM,
    6. Shevrin I,
    7. Du H,
    8. Peterson LR,
    9. Robicsek A
    . 2013. Predictors and molecular epidemiology of community-onset extended-spectrum β-lactamase-producing Escherichia coli infection in a Midwestern community. Infect Control Hosp Epidemiol 34:947–953. doi:10.1086/671725.
    OpenUrlCrossRef
  6. 6.↵
    1. Rogers BA,
    2. Ingram PR,
    3. Runnegar N,
    4. Pitman MC,
    5. Freeman JT,
    6. Athan E,
    7. Havers SM,
    8. Sidjabat HE,
    9. Jones M,
    10. Gunning E,
    11. De Almeida M,
    12. Styles K,
    13. Paterson DL
    , Australasian Society for Infectious Diseases Clinical Research Network. 2014. Community-onset Escherichia coli infection resistant to expanded-spectrum cephalosporins in low-prevalence countries. Antimicrob Agents Chemother 58:2126–2134. doi:10.1128/AAC.02052-13.
    OpenUrlAbstract/FREE Full Text
  7. 7.↵
    1. den Reijer PM,
    2. van Burgh S,
    3. Burggraaf A Ossewaarde JM,
    4. van der Zee A
    . 2016. The widespread presence of a multidrug-resistant Escherichia coli ST131 clade among community-associated and hospitalized patients. PLoS One 15:e0150420. doi:10.1371/journal.pone.0150420.
    OpenUrlCrossRef
  8. 8.↵
    1. Madigan T,
    2. Johnson JR,
    3. Clabots C,
    4. Johnston BD,
    5. Porter SB,
    6. Slater BS,
    7. Banerjee R
    . 2015. Extensive household outbreak of urinary tract infection and intestinal colonization due to extended-spectrum β-lactamase-producing Escherichia coli sequence type 131. Clin Infect Dis 61:e5–e12. doi:10.1093/cid/civ273.
    OpenUrlCrossRefPubMed
  9. 9.↵
    1. Torres E,
    2. López-Cerero L,
    3. Morales I,
    4. Navarro MD,
    5. Rodríguez-Baño J,
    6. Pascual A
    . 2018. Prevalence and transmission dynamics of Escherichia coli ST131 among contacts of infected community and hospitalized patients. Clin Microbiol Infect 24:618–623. doi:10.1016/j.cmi.2017.09.007.
    OpenUrlCrossRef
  10. 10.↵
    1. Kim YA,
    2. Kim JJ,
    3. Kim H,
    4. Lee K
    . 2017. Community-onset extended-spectrum-β-lactamase-producing Escherichia coli sequence type 131 at two Korean community hospitals: the spread of multidrug-resistant E. coli to the community via healthcare facilities. Int J Infect Dis 54:39–42. doi:10.1016/j.ijid.2016.11.010.
    OpenUrlCrossRef
  11. 11.↵
    1. Chung HC,
    2. Lai CH,
    3. Lin JN,
    4. Huang CK,
    5. Liang SH,
    6. Chen WF,
    7. Shih YC,
    8. Lin HH,
    9. Wang JL
    . 2012. Bacteremia caused by Escherichia coli sequence type ST131 and non-ST131 clones: comparison of demographic data, clinical features, and mortality. Antimicrob Agents Chemother 56:618–622. doi:10.1128/AAC.05753-11.
    OpenUrlAbstract/FREE Full Text
  12. 12.↵
    1. Mo Y,
    2. Harris PNA,
    3. Lye DC,
    4. Jureen R,
    5. Paterson D
    . 2016. Emergence of community-onset cefotaxime non-susceptible Escherichia coli ST131 bloodstream infections in Singapore hospitals. Abstr Soc Healthc Epidemiol Am Spring Conf, Atlanta, GA, 18 to 21 May 2016.
  13. 13.↵
    1. Al-Hasan MN,
    2. Lahr BD,
    3. Eckel-Passow JE,
    4. Baddour LM
    . 2009. Antimicrobial resistance trends of Escherichia coli bloodstream isolates: a population-based study, 1998-2007. J Antimicrob Chemother 64:169–174. doi:10.1093/jac/dkp162.
    OpenUrlCrossRefPubMedWeb of Science
  14. 14.↵
    1. Baddour LM,
    2. Banerjee R
    . 2012. Incidence of antibiotic-resistant Escherichia coli bacteriuria according to age and location of onset: a population-based study from Olmsted County, Minnesota. Mayo Clin Proc 87:753–775. doi:10.1016/j.mayocp.2012.02.025.
    OpenUrlCrossRefPubMed
  15. 15.↵
    1. Hsu LY,
    2. Tan TY,
    3. Jureen R,
    4. Koh TH,
    5. Krishnan P,
    6. Tzer-Pin Lin R,
    7. Wen-Sin Tee N,
    8. Tambyah PA
    . 2007. Antimicrobial drug resistance in Singapore hospitals. Emerg Infect Dis 13:1944–1947. doi:10.3201/eid1312.070299.
    OpenUrlCrossRefPubMedWeb of Science
  16. 16.↵
    1. Johnson JR,
    2. Tchesnokova V,
    3. Johnston B,
    4. Clabots C,
    5. Roberts PL,
    6. Billig M,
    7. Riddell K,
    8. Rogers P,
    9. Qin X,
    10. Butler-Wu S,
    11. Price LB,
    12. Aziz M,
    13. Debroy C,
    14. Robicsek A,
    15. Hansen G,
    16. Urban C,
    17. Platell J,
    18. Trott DJ,
    19. Zhanel G,
    20. Weissman SJ,
    21. Cookson BT,
    22. Fang FC,
    23. Limaye AP,
    24. Scholes D,
    25. Chattopadhyay S,
    26. Hooper DC,
    27. Sokurenko EV
    . 2013. Abrupt emergence of a single dominant multidrug-resistant strain of Escherichia coli. J Infect Dis 207:919–928. doi:10.1093/infdis/jis933.
    OpenUrlCrossRefPubMed
  17. 17.↵
    1. Bukh AS,
    2. Schønheyder HC,
    3. Emmersen JMG,
    4. Søgaard M,
    5. Bastholm S,
    6. Roslev P
    . 2009. Escherichia coli phylogenetic groups are associated with site of infection and level of antibiotic resistance in community-acquired bacteraemia: a 10 year population-based study in Denmark. J Antimicrob Chemother 64:163–168. doi:10.1093/jac/dkp156.
    OpenUrlCrossRefPubMedWeb of Science
  18. 18.↵
    1. Clermont O,
    2. Couffignal C,
    3. Blanco J,
    4. Mentré F,
    5. Picard B,
    6. Denamur E
    , COLIVILLE and COLIBAFI Groups. 2017. Two levels of specialization in bacteraemic Escherichia coli strains revealed by their comparison with commensal strains. Epidemiol Infect 145:872–882. doi:10.1017/S0950268816003010.
    OpenUrlCrossRef
  19. 19.↵
    1. Lefort A,
    2. Panhard X,
    3. Clermont O,
    4. Woerther PL,
    5. Branger C,
    6. Mentré F,
    7. Fantin B,
    8. Wolff M,
    9. Denamur E
    , COLIBAFI Group. 2011. Host factors and portal of entry outweigh bacterial determinants to predict the severity of Escherichia coli bacteremia. J Clin Microbiol 49:777–783. doi:10.1128/JCM.01902-10.
    OpenUrlCrossRefPubMed
  20. 20.↵
    1. Johnson JR,
    2. Porter S,
    3. Thuras P,
    4. Castanheira M
    . 2017. The pandemic H30 subclone of sequence type 131 (ST131) as the leading cause of multidrug-resistant Escherichia coli infections in the United States (2011–2012). Open Forum Infect Dis 4:ofx089. doi:10.1093/ofid/ofx089.
    OpenUrlCrossRef
  21. 21.↵
    1. Gibreel TM,
    2. Dodgson AR,
    3. Cheesbrough J,
    4. Bolton FJ,
    5. Fox AJ,
    6. Upton M
    . 2012. High metabolic potential may contribute to the success of ST131 uropathogenic Escherichia coli. J Clin Microbiol 50:3202–3207. doi:10.1128/JCM.01423-12.
    OpenUrlAbstract/FREE Full Text
  22. 22.↵
    1. Johnson JR,
    2. Thuras P,
    3. Johnston BD,
    4. Weissman SJ,
    5. Limaye AP,
    6. Riddell K,
    7. Scholes D,
    8. Tchesnokova V,
    9. Sokurenko E
    . 2016. The pandemic H30 subclone of Escherichia coli sequence type 131 is associated with persistent infections and adverse outcomes independent from its multidrug resistance and associations with compromised hosts. Clin Infect Dis 62:1529–1536. doi:10.1093/cid/ciw193.
    OpenUrlCrossRefPubMed
  23. 23.↵
    1. Hsu L,
    2. Tan T,
    3. Tam VH,
    4. Kwa A,
    5. Fisher DA,
    6. Koh TH
    , Network for Antimicrobial Resistance Surveillance (Singapore). 2010. Surveillance and correlation of antibiotic prescription and resistance of Gram-negative bacteria in Singaporean hospitals. Antimicrob Agents Chemother 54:1173–1178. doi:10.1128/AAC.01076-09.
    OpenUrlAbstract/FREE Full Text
  24. 24.↵
    1. Young BE,
    2. Lye DC,
    3. Krishnan P,
    4. Chan SP,
    5. Leo YS
    . 2014. A prospective observational study of the prevalence and risk factors for colonization by antibiotic resistant bacteria in patients at admission to hospital in Singapore. BMC Infect Dis 14:298. doi:10.1186/1471-2334-14-298.
    OpenUrlCrossRefPubMed
  25. 25.↵
    Center for Disease Dynamics, Economics, and Policy. 2015. Antibiotic use. Center for Disease Dynamics, Economics, and Policy, Washington, DC. https://resistancemap.cddep.org/AntibioticUse.php. Accessed 10 March 2018.
  26. 26.↵
    Center for Disease Dynamics, Economics, and Policy. 2012. Use map. United States. Center for Disease Dynamics, Economics, and Policy, Washington, DC. https://resistancemap.cddep.org/CountryPageSub.php?countryId=38&country=United+States. Accessed 10 March 2018.
  27. 27.↵
    Centers for Disease Control and Prevention. 2015. Antibiotic resistance patient safety atlas: antibiotic prescriptions dispensed in US community pharmacies per 1000 population 2015. Centers for Disease Control and Prevention, Atlanta, GA. https://gis.cdc.gov/grasp/PSA/AUMapView.html. Accessed 10 March 2018.
  28. 28.↵
    1. Lim EJ,
    2. Ho SX,
    3. Cao DY,
    4. Lau QC,
    5. Koh TH,
    6. Hsu LY
    . 2016. Extended-spectrum beta-lactamase-producing Enterobacteriaceae in retail chicken meat in Singapore. Ann Acad Med Singapore 45:557–559.
    OpenUrl
  29. 29.↵
    1. Paterson DL,
    2. Ko W,
    3. Von Gottberg A,
    4. Casellas JM,
    5. Mulazimoglu L,
    6. Klugman KP,
    7. Bonomo RA,
    8. Rice LB,
    9. McCormack JG,
    10. Yu VL
    . 2001. Outcome of cephalosporin treatment for serious infections due to apparently susceptible organisms producing implications for the clinical microbiology laboratory. J Clin Microbiol 39:2206–2212. doi:10.1128/JCM.39.6.2206-2212.2001.
    OpenUrlAbstract/FREE Full Text
  30. 30.↵
    1. Lautenbach E,
    2. Patel JB,
    3. Bilker WB,
    4. Edelstein PH,
    5. Fishman NO
    . 2001. Extended spectrum beta lactamase producing Escherichia coli and Klebsiella pneumoniae: risk factors for infection and impact of resistance on outcomes. Clin Infect Dis 32:1162–1171. doi:10.1086/319757.
    OpenUrlCrossRefPubMedWeb of Science
  31. 31.↵
    1. Tchesnokova V,
    2. Avagyan H,
    3. Rechkina E,
    4. Chan D,
    5. Muradova M,
    6. Haile HG,
    7. Radey M,
    8. Weissman S,
    9. Riddell K,
    10. Scholes D,
    11. Johnson JR,
    12. Sokurenko EV
    . 2017. Bacterial clonal diagnostics as a tool for evidence-based empiric antibiotic selection. PLoS One 12:e0174132. doi:10.1371/journal.pone.0174132.
    OpenUrlCrossRef
  32. 32.↵
    1. Tchesnokova V,
    2. Billig M,
    3. Chattopadhyay S,
    4. Linardopoulou E,
    5. Aprikian P,
    6. Roberts PL,
    7. Skrivankova V,
    8. Johnston B,
    9. Gileva A,
    10. Igusheva I,
    11. Toland A,
    12. Riddell K,
    13. Rogers P,
    14. Qin X,
    15. Butler-Wu S,
    16. Cookson BT,
    17. Fang FC,
    18. Kahl B,
    19. Price LB,
    20. Weissman SJ,
    21. Limaye A,
    22. Scholes D,
    23. Johnson JR,
    24. Sokurenko EV
    . 2013. Predictive diagnostics for Escherichia coli infections based on the clonal association of antimicrobial resistance and clinical outcome. J Clin Microbiol 51:2991–2999. doi:10.1128/JCM.00984-13.
    OpenUrlAbstract/FREE Full Text
  33. 33.↵
    1. Drekonja DM,
    2. Kuskowski MA,
    3. Anway R,
    4. Johnston BD,
    5. Johnson JR
    . 2016. The niche for Escherichia coli sequence type 131 among veterans: urinary tract abnormalities and long-term care facilities. Open Forum Infect Dis 3:ofw138. doi:10.1093/ofid/ofw138.
    OpenUrlCrossRef
  34. 34.↵
    1. Banerjee R,
    2. Teng CB,
    3. Cunningham SA,
    4. Ihde SM,
    5. Steckelberg JM,
    6. Moriarty JP,
    7. Shah ND,
    8. Mandrekar JN,
    9. Patel R
    . 2015. Randomized trial of rapid multiplex polymerase chain reaction-based blood culture identification and susceptibility testing. Clin Infect Dis 61:1071–1080. doi:10.1093/cid/civ447.
    OpenUrlCrossRefPubMed
  35. 35.↵
    1. Andrews JM
    , BSAC Working Party on Susceptibility Testing. 2005. BSAC standardized disc susceptibility testing method (version 4). J Antimicrob Chemother 56:60–76. doi:10.1093/jac/dki124.
    OpenUrlCrossRefPubMedWeb of Science
  36. 36.↵
    CLSI. 2015. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically, 10th ed. CLSI document M07-A10. CLSI, Wayne, PA.
  37. 37.↵
    CLSI. 2014. Performance standards for antimicrobial susceptibility testing, 24th ed. CLSI document M100-S24. CLSI, Wayne, PA.
  38. 38.↵
    EUCAST. 2013. EUCAST guidelines for detection of resistance mechanisms and specific resistances of clinical and/or epidemiological importance. Version 1.0. http://www.eucast.org/fileadmin/src/media/PDFs/EUCAST_files/Resistance_mechanisms/EUCAST_detection_of_resistance_mechanisms_v1.0_20131211.pdf. Accessed 1 September 2017.
  39. 39.↵
    1. Clermont O,
    2. Christenson JK,
    3. Denamur E,
    4. Gordon DM
    . 2013. The Clermont Escherichia coli phylo-typing method revisited: improvement of specificity and detection of new phylo-groups. Environ Microbiol Rep 5:58–65. doi:10.1111/1758-2229.12019.
    OpenUrlCrossRefPubMed
  40. 40.↵
    1. Colpan A,
    2. Johnston B,
    3. Porter S,
    4. Clabots C,
    5. Anway R,
    6. Thao L,
    7. Kuskowski MA,
    8. Tchesnokova V,
    9. Sokurenko EV,
    10. Johnson JR,
    11. Allen BL,
    12. Baracco GJ,
    13. Bedimo R,
    14. Bessesen M,
    15. Bonomo RA,
    16. Brecher SM,
    17. Brown ST,
    18. Castellino L,
    19. Desai AS,
    20. Fernau F,
    21. Fisher MA,
    22. Fleckenstein J,
    23. Fleming CS,
    24. Fries NJ,
    25. Kan VL,
    26. Kauffman CA,
    27. Klutts S,
    28. Ohl M,
    29. Russo T,
    30. Swiatlo A,
    31. Swiatlo E
    . 2013. Escherichia coli sequence type 131 (ST131) subclone H30 as an emergent multidrug-resistant pathogen among US veterans. Clin Infect Dis 57:1256–1265. doi:10.1093/cid/cit503.
    OpenUrlCrossRefPubMed
  41. 41.↵
    1. Weissman SJ,
    2. Johnson JR,
    3. Tchesnokova V,
    4. Billig M,
    5. Dykhuizen D,
    6. Riddell K,
    7. Rogers P,
    8. Qin X,
    9. Butler-Wu S,
    10. Cookson BT,
    11. Fang FC,
    12. Scholes D,
    13. Chattopadhyay S,
    14. Sokurenko E
    . 2012. High-resolution two-locus clonal typing of extraintestinal pathogenic Escherichia coli. Appl Environ Microbiol 78:1353–1360. doi:10.1128/AEM.06663-11.
    OpenUrlAbstract/FREE Full Text
  42. 42.↵
    1. Clermont O,
    2. Christenson JK,
    3. Daubié AS,
    4. Gordon DM,
    5. Denamur E
    . 2014. Development of an allele-specific PCR for Escherichia coli B2 sub-typing, a rapid and easy to perform substitute of multilocus sequence typing. J Microbiol Methods 101:24–27. doi:10.1016/j.mimet.2014.03.008.
    OpenUrlCrossRefPubMed
  43. 43.↵
    1. Xu L,
    2. Ensor V,
    3. Gossain S,
    4. Nye K,
    5. Hawkey P
    . 2005. Rapid and simple detection of blaCTX-M genes by multiplex PCR assay. J Med Microbiol 54:1183–1187. doi:10.1099/jmm.0.46160-0.
    OpenUrlCrossRefPubMedWeb of Science
  44. 44.↵
    1. Johnson JR,
    2. Stell AL
    . 2000. Extended virulence genotypes of Escherichia coli strains from patients with urosepsis in relation to phylogeny and host compromise. J Infect Dis 181:261–272. doi:10.1086/315217.
    OpenUrlCrossRefPubMedWeb of Science
  45. 45.↵
    1. Friedman ND,
    2. Kaye KS,
    3. Stout JE,
    4. Mcgarry SA,
    5. Trivette SL,
    6. Briggs JP,
    7. Lamm W,
    8. Clark C,
    9. Macfarquhar J,
    10. Walton AL,
    11. Reller LB,
    12. Sexton DJ
    . 2002. Health care-associated bloodstream infections in adults: a reason to change the accepted definition of community-acquired infections. Ann Intern Med 137:791–798. doi:10.7326/0003-4819-137-10-200211190-00007.
    OpenUrlCrossRefPubMedWeb of Science
  46. 46.↵
    1. Chow JW,
    2. Fine MJ,
    3. Shlaes DM,
    4. Quinn JP,
    5. Hooper DC,
    6. Johnson MP,
    7. Ramphal R,
    8. Wagener MM,
    9. Miyashiro DK,
    10. Yu VL
    . 1991. Enterobacter bacteremia: clinical features and emergence of antibiotic resistance during therapy. Ann Intern Med 115:585–590. doi:10.7326/0003-4819-115-8-585.
    OpenUrlCrossRefPubMedWeb of Science
  • Copyright © 2018 American Society for Microbiology.

All Rights Reserved.

PreviousNext
Back to top
Download PDF
Citation Tools
Clinical and Molecular Correlates of Escherichia coli Bloodstream Infection from Two Geographically Diverse Centers in Rochester, Minnesota, and Singapore
Shehara M. Mendis, Shawn Vasoo, Brian D. Johnston, Stephen B. Porter, Scott A. Cunningham, Sanjay R. Menon, Christine B. Teng, Partha P. De, Robin Patel, James R. Johnson, Ritu Banerjee
Antimicrobial Agents and Chemotherapy Sep 2018, 62 (10) e00937-18; DOI: 10.1128/AAC.00937-18

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Print

Alerts
Sign In to Email Alerts with your Email Address
Email

Thank you for sharing this Antimicrobial Agents and Chemotherapy article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Clinical and Molecular Correlates of Escherichia coli Bloodstream Infection from Two Geographically Diverse Centers in Rochester, Minnesota, and Singapore
(Your Name) has forwarded a page to you from Antimicrobial Agents and Chemotherapy
(Your Name) thought you would be interested in this article in Antimicrobial Agents and Chemotherapy.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Clinical and Molecular Correlates of Escherichia coli Bloodstream Infection from Two Geographically Diverse Centers in Rochester, Minnesota, and Singapore
Shehara M. Mendis, Shawn Vasoo, Brian D. Johnston, Stephen B. Porter, Scott A. Cunningham, Sanjay R. Menon, Christine B. Teng, Partha P. De, Robin Patel, James R. Johnson, Ritu Banerjee
Antimicrobial Agents and Chemotherapy Sep 2018, 62 (10) e00937-18; DOI: 10.1128/AAC.00937-18
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Top
  • Article
    • ABSTRACT
    • INTRODUCTION
    • RESULTS
    • DISCUSSION
    • MATERIALS AND METHODS
    • ACKNOWLEDGMENTS
    • FOOTNOTES
    • REFERENCES
  • Figures & Data
  • Info & Metrics
  • PDF

KEYWORDS

Escherichia coli
bacteremia
ST131
H30Rx
medical outcomes
virulence factors

Related Articles

Cited By...

About

  • About AAC
  • Editor in Chief
  • Editorial Board
  • Policies
  • For Reviewers
  • For the Media
  • For Librarians
  • For Advertisers
  • Alerts
  • AAC Podcast
  • RSS
  • FAQ
  • Permissions
  • Journal Announcements

Authors

  • ASM Author Center
  • Submit a Manuscript
  • Article Types
  • Ethics
  • Contact Us

Follow #AACJournal

@ASMicrobiology

       

ASM Journals

ASM journals are the most prominent publications in the field, delivering up-to-date and authoritative coverage of both basic and clinical microbiology.

About ASM | Contact Us | Press Room

 

ASM is a member of

Scientific Society Publisher Alliance

 

American Society for Microbiology
1752 N St. NW
Washington, DC 20036
Phone: (202) 737-3600

Copyright © 2021 American Society for Microbiology | Privacy Policy | Website feedback

Print ISSN: 0066-4804; Online ISSN: 1098-6596